Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5362016 | 1.00 | ALDH1A1 (0.46) | ALDH1A1DDB1CRBNHCAR2GRM5 | |
| SCHEMBL13166364 | 0.88 | ALDH1A1 (0.50) | ALDH1A1DDB1CRBNHCAR2GRM5 | |
| SCHEMBL5370676 | 0.88 | TDP1 (0.51) | L3MBTL1SLC6A3TDP1 | |
| SCHEMBL5370679 | 0.88 | TDP1 (0.51) | L3MBTL1SLC6A3TDP1 | |
| SCHEMBL5361661 | 0.87 | MEN1 (0.39) | ALDH1A1MAPK1L3MBTL1KMT2A | |
| SCHEMBL5367568 | 0.85 | ALDH1A1 (0.47) | ALDH1A1DDB1CRBNHCAR2GRM5 | |
| SCHEMBL5367562 | 0.85 | ALDH1A1 (0.47) | ALDH1A1DDB1CRBNHCAR2GRM5 | |
| SCHEMBL5364939 | 0.84 | ALDH1A1 (0.46) | ALDH1A1DDB1CRBNHCAR2GRM5 | |
| SCHEMBL5364945 | 0.84 | ALDH1A1 (0.46) | ALDH1A1DDB1CRBNHCAR2GRM5 | |
| SCHEMBL5377618 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276622-B2 | Method for producing oxygen-containing compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-10-02 | — | — | US | disclosed |
| US-20060173221-A1 | Method for producing oxygen-containing compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1609777-A1 | METHOD FOR PRODUCING OXYGEN-CONTAINING COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173221-A1 | Method for producing oxygen-containing compound | GPX4, DUOX2, SCO2 | ALDH1A1 863/4885DDB1 2590/4885CRBN 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.